This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
This significant milestone enhances our global regulatory standing
These observations are procedural in nature and none of them are related to data integrity
The FDA issued Form 483 with one observation related to building and facility management
The Q1 2025 also witnessed a successful launch of Allegra D
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Subscribe To Our Newsletter & Stay Updated
